Subscribe
29 October 2013Asia

Bayer’s compulsory licence appeal set to start in India

A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
Bayer takes another swipe at Nexavar compulsory licence
15 October 2013   Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.
Big Pharma
India rejects Bayer plea over compulsory licence
4 March 2013   India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Asia
Bayer takes another swipe at Nexavar compulsory licence
15 October 2013   Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.
Big Pharma
India rejects Bayer plea over compulsory licence
4 March 2013   India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.

More on this story

Asia
Bayer takes another swipe at Nexavar compulsory licence
15 October 2013   Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.
Big Pharma
India rejects Bayer plea over compulsory licence
4 March 2013   India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.

More features

Gene tech firm fends off injunction in test kit dispute
Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve